October 2023

'Infinitely searchable' and the dynamic nature of innovation

All I need are two words to describe how Serva is revolutionizing the technology behind the production of radioisotopes: infinitely searchable.

Our massive collection of standardized data—all bundled up into what we lovingly refer to as the Isotope Tracker 9000—has given us all possible pathways of isotope production. This incredible technology allows us to manipulate the data any way we want to find the best path forward to developing any number of isotopes—many of them in high demand.

These days, the isotope everyone wants is Actinium-225—our cancer-fighting, life-saving Targeted Alpha Therapy (TAT) isotope that made headlines last summer when we announced our novel reactor-based production method capable of dramatically increasing the supply of Ac-225 without huge investments in infrastructure.

The response has been incredible.

Building off this success, we have entered new waters. We've got the technology—now, we're looking to scale.

And, in breaking news, reported here for the first time, MIT has validated our measurement of Ac-225, joining the prestigious Mayo Clinic.

We are now engaging with partners worldwide—a blend of radiopharmaceutical companies, manufacturing organizations, nuclear reactors, and the list goes on.

Serva recently became a member of the Canadian Nuclear Isotope Council, a key partner in the innovative and growing Canadian isotope production ecosystem. (You can read about that further down.)

As we engage with more companies around our isotope technology, we can't help but wonder about the dynamic nature of innovation—the way ideas build and innovation evolves, creating altogether new ways of doing things. (Just look at the seismic shifts taking place in nuclear today.)

And in case you forgot, Serva originated as a fuels company with a mission to design new technologies that manipulate the nuclear reactor environment to make things run smoother, safer, better.

In doing that, we discovered a new way of developing isotopes and demonstrated our technology as a powerful cancer cure—using the technology designed to produce clean energy.

Just imagine what our technology can do—when it's used to do exactly what it’s designed to.

Onward,

Ian

Sneak peak: MIT validates Serva's reactor-based method to produce Actinium-225 isotope

Serva Energy’s sample measurement of Actinium-225 (Ac-225) has been validated by the MIT Nuclear Research Laboratory—the latest milestone in Serva’s development of commercial quantities of Ac-225.

“In this new report, some of the best scientists in the world have demonstrated the power of our technology as a cancer treatment,” said Ian Horvath, CEO and founder of Serva Energy. “Producing medical-grade Actinium was never our goal, but it has become a compelling backstory in the evolution of our technology, which is designed to change the way we produce carbon-free energy—making it safer, sustainable, and more efficient.”

In June, Serva announced a new reactor-based production method to create significantly greater amounts of medical-grade Ac-225—marking the first time a commercial entity has used a conventional reactor to produce the life-saving isotope.

"MIT’s confirmation of the successful production of Ac-225 using Serva’s innovative process, combined with the initial confirmation performed by the Mayo Clinic, is highly encouraging," said Dr. Ian Horn, Senior Associate Consultant at the Mayo Clinic Rochester. "Plans to quickly optimize and scale up any production of this potentially critical medical isotope will be crucial in establishing a reliable supply of Ac-225."

Serva’s technology, which transforms Radium-226, considered waste and highly restricted, into Ac-225, is at the forefront of a paradigm shift in nuclear processes—one in which nuclear waste serves as a resource, an asset to harness, reducing the amount of waste that needs to be managed. 

“At Serva, we are creating a whole new way of thinking about nuclear waste by using it as fuel for the reactor and as a seed material for producing much needed isotopes,” said Horvath. “Nothing needs to be managed or destroyed, as it’s all part of the process.”

Mayo Clinic’s Dr. Horn, who specializes in Radiochemistry and Radiopharmaceuticals in the Departments of Nuclear Medicine and Radiology, added: "Serva’s production method could provide sufficient quantities to serve the anticipated demand for the successful development of a pipeline of Ac-225-based Targeted Alpha Therapy products for widespread clinical use. These novel products have a strong potential to positively impact a significant and growing patient population for whom this type of therapy promises to be highly beneficial."

Serva joins Canadian Nuclear Isotope Council

Serva Energy has announced a partnership with the Canadian Nuclear Isotope Council (CNIC), an essential advocate for the world’s supply of a diverse portfolio of isotopes.

As the newest member of the CNIC, Serva seeks to engage with the growing Canadian isotope market—leveraging and developing new technologies and providing the tools necessary to produce needed isotopes for novel cancer treatments.

“We are excited about this partnership and its potential to deliver critical solutions and supplies to the radiopharmaceutical industry,” said Ian Horvath, CEO and founder of Serva. “We see this partnership with the CNIC as a triple win for Serva, Canadian partners, and patients in North America and around the world.”

Read more:

Serva Energy joins CNIC to revolutionize how radioisotopes are produced in Canada 

Once again, thank you to our investors!

What an incredible time to be with Serva! On behalf of the company, I want to express my deepest gratitude to all who have supported this amazing journey. Just look at how far we've come! We couldn't have done it without our investors whose contributions have propelled us forward at lightning speed. Thank you.

Greg Anderson

Chief Operating Officer

Nuclear is awesome! Ian Horvath talks with children about spectroscopy at the 2023 Nuclear Science Week National Expo Event, on Saturday, October 14. The event, led by the National Museum of Nuclear Science & History, a Smithsonian Affiliate Institution, brought together over 1,200 people—students, educators, and researchers—for a day of learning and fun around nuclear science and innovation.